What is the Historic and Current Scenario of the Adalimumab, Infliximab and Etanercept Biosimilars Market?
The adalimumab, infliximab and etanercept biosimilars market has seen considerable growth due to a variety of factors.
• The market size for biosimilars like adalimumab, infliximab, and etanercept has exponentially expanded in the past few years. It will escalate from $4.37 billion in 2024 to $4.98 billion in 2025, marking a compound annual growth rate (CAGR) of 14.1%.
The surge in growth during the historic period can be associated with a rise in healthcare spending, amendments in regulatory policies, government policies, and soaring healthcare expenses.
What are the Forecasted Growth and Key Factors of the Adalimumab, Infliximab and Etanercept Biosimilars Market?
The adalimumab, infliximab and etanercept biosimilars market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of biosimilars for adalimumab, infliximab, and etanercept is poised to experience a swift expansion in the near future. It is projected to rise to $7.44 billion by 2029, with a CAGR of 10.5%.
This anticipated expansion in the forecast period can be ascribed to increased healthcare spending, an aging demographic, and enhanced access to healthcare services propelling this market's growth. Key trends foreseen in the aforementioned period involve efforts towards product launching, mergers and acquisitions, the establishment of strategic alliances, and heightened investment activities.
What Are the Critical Driver Fuelling the Adalimumab, Infliximab and Etanercept Biosimilars Market's Growth?
The entry of biosimilars into the adalimumab, infliximab, and etanercept biosimilars market is facilitated by the patent expiration of branded medications. For example, Inflectra, a product of Hospira (a subsidiary of Pfizer Inc.), was authorized by the FDA in the US for the treatment of multiple autoimmune disorders like rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis, following the patent expiration of the branded medication, Remicade. Also, the expiration of Amgen's Enbrel patent in the EU paved the way for the approval of Benepali (a biosimilar of Enbrel) by the European Commission. The patent for Humira also expired, making its biosimilars accessible in the market. Lately, the FDA has given approval to Hulio, Humira's sixth biosimilar. Subsequently, the demand for adalimumab, infliximab, and etanercept biosimilars in the market will be propelled by the patent expiration of branded biologic drugs like Humira, Enbrel, and Remicade.
How Is the Adalimumab, Infliximab and Etanercept Biosimilars Market segmented?
The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –
1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications
Subsegments:
1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others
2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others
3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development
Pre-Book The Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the Adalimumab, Infliximab and Etanercept Biosimilars Market?
Leading businesses within the adalimumab, infliximab, and etanercept biosimilars market are concentrating on creating new and improved products, one of which is the citrate-free adalimumab, to provide consistent quality services to their clients. This is an iteration of the biologic medicine adalimumab, only without citrate. A case in point is from December 2022 when a Germany-based pharmaceutical and medical device company, Fresenius Kabi, announced U.S. FDA approval for its biosimilar Idacio (adalimumab). This product is for managing chronic autoimmune disorders, covering all approved uses of the reference product. Additionally, advanced analytical methods were utilized in its pharmaceutical development to cater to multiple chronic conditions.
Who Are the Key Players in the Adalimumab, Infliximab and Etanercept Biosimilars Market?
Major companies operating in the adalimumab
• infliximab and etanercept biosimilars market include:
• Biogen
• Novartis (Sandoz)
• Pfizer
• Amgen
• Celltrion
• Samsung Bioepis (Samsung Biologics)
• Hetero Drugs Limited
• Fresenius Kabi AG
• Boehringer Ingelheim
• Biocon
• Zydus Lifesciences Limited
• Reliance Life Sciences
• Torrent Pharmaceuticals Ltd
• Sun Pharmaceutical Industries Ltd
• Cipla Limited
• Zhejiang Hisun Pharmaceutical Co. Ltd
• Bio-Thera Solutions. Ltd
• Innovent Biologics (Suzhou) Co. Ltd
• Janssen Biologics BV
• Shanghai CP Guojian Pharmaceutical Co. Ltd
• Sansheng Guojian
• Shanghai Junshi Biosciences Co. Ltd
• Mabwell Bioscience Co. Ltd
• LG Chem
• Nippon Kayaku
• Mochida Pharmaceutical Co. Ltd
• mAbxience
• Allergan
• Microgen
• Geropharm
• Valenta
• NovaMedica Veropharm
• Biocad
• Roche
• Bristol-Myers Squibb
• Celon Pharma
• SynBio
• Ache
• Eurofarma
• Teva Pharmaceuticals
• Oramed Pharmaceuticals
• Entera Bio
• Julphar
• Hikma Pharmaceuticals
• Mylan
• BIOPHARMA-MEA
• NeoTX
• AID Genomics Limited
• Altis Biologics
• Next Biosciences
• Viome
• Inqaba Biotechnical Industries (Pty) Ltd
What Is The Most Dominant Region In The Adalimumab, Infliximab and Etanercept Biosimilars Market?
North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
